ASCO: Trial compares common adjuvant treatments for pancreatic cancer

Bookmark and Share
Published: 18 Jun 2009
Views: 13222
Dr. John Neoptolemos - University of Liverpool, Liverpool, UK
ASCO press conference: A phase III trial comparing the adjuvant treatments most commonly used for pancreatic cancer in the United States and Europe (gemcitabine and 5- FU/FA, respectively) found that there is no difference in survival between the two regimens, though gemcitabine was associated with fewer side effects.